Cargando…

Sialyltransferase Inhibitor Ac(5)3F(ax)Neu5Ac Reverts the Malignant Phenotype of Pancreatic Cancer Cells, and Reduces Tumor Volume and Favors T-Cell Infiltrates in Mice

SIMPLE SUMMARY: An increase of sialic acid in the cancer cells’ surface is a hallmark of tumours, including pancreatic cancer, and it has been related to tumour malignancy and immune suppression. In this work, we have assessed for the first time the potential of the sialyltransferase inhibitor, Ac(5...

Descripción completa

Detalles Bibliográficos
Autores principales: Miró, Laura, López, Júlia, Guerrero, Pedro E., Martínez-Bosch, Neus, Manero-Rupérez, Noemí, Moreno, Mireia, Ortiz, M. Rosa, Llop, Esther, Navarro, Pilar, Peracaula, Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776040/
https://www.ncbi.nlm.nih.gov/pubmed/36551619
http://dx.doi.org/10.3390/cancers14246133
_version_ 1784855780473700352
author Miró, Laura
López, Júlia
Guerrero, Pedro E.
Martínez-Bosch, Neus
Manero-Rupérez, Noemí
Moreno, Mireia
Ortiz, M. Rosa
Llop, Esther
Navarro, Pilar
Peracaula, Rosa
author_facet Miró, Laura
López, Júlia
Guerrero, Pedro E.
Martínez-Bosch, Neus
Manero-Rupérez, Noemí
Moreno, Mireia
Ortiz, M. Rosa
Llop, Esther
Navarro, Pilar
Peracaula, Rosa
author_sort Miró, Laura
collection PubMed
description SIMPLE SUMMARY: An increase of sialic acid in the cancer cells’ surface is a hallmark of tumours, including pancreatic cancer, and it has been related to tumour malignancy and immune suppression. In this work, we have assessed for the first time the potential of the sialyltransferase inhibitor, Ac(5)3F(ax)Neu5Ac, to reduce tumor sialylation in pancreatic cancer and to revert its malignant phenotype. We have shown that Ac(5)3F(ax)Neu5Ac treatment on human pancreatic cancer cells decreased their sialic acid, reduced their E-selectin adhesion—the prior step to tumour extravasation—and their migration and invasion capabilities. In addition, subcutaneous pancreatic tumours generated on immunocompetent mice that were treated with Ac(5)3F(ax)Neu5Ac showed a reduced growth and increased tumour infiltrating lymphocytes. These results show that the targeting of tumour sialoglycans in pancreatic cancer reverts its malignant phenotype and favours anti-tumour immune surveillance, which opens the way to use sialyltransferase inhibitors as a novel therapeutic strategy against this dismal disease. ABSTRACT: Hypersialylation is a feature of pancreatic ductal adenocarcinoma (PDA) and it has been related to tumor malignancy and immune suppression. In this work, we have evaluated the potential of the sialyltransferase inhibitor, Ac(5)3F(ax)Neu5Ac, to decrease tumor sialoglycans in PDA and to revert its malignant phenotype. Sialoglycans on PDA cells were evaluated by flow cytometry, and the functional impact of Ac(5)3F(ax)Neu5Ac was assessed using E-selectin adhesion, migration, and invasion assays. PDA tumors were generated in syngeneic mice from KC cells and treated with Ac(5)3F(ax)Neu5Ac to evaluate tumor growth, mice survival, and its impact on blocking sialic acid (SA) and on the tumor immune component. Ac(5)3F(ax)Neu5Ac treatment on human PDA cells decreased α2,3-SA and sialyl-Lewis(x), which resulted in a reduction in their E-selectin adhesion, and in their migratory and invasive capabilities. Subcutaneous murine tumors treated with Ac(5)3F(ax)Neu5Ac reduced their volume, their SA expression, and modified their immune component, with an increase in CD8(+) T-lymphocytes and NK cells. In conclusion, Ac(5)3F(ax)Neu5Ac treatment weakened PDA cells’ malignant phenotype, thereby reducing tumor growth while favoring anti-tumor immune surveillance. Altogether, these results show the positive impact of reducing SA expression by inhibiting cell sialyltransferases and open the way to use sialyltransferase inhibitors to target this dismal disease.
format Online
Article
Text
id pubmed-9776040
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97760402022-12-23 Sialyltransferase Inhibitor Ac(5)3F(ax)Neu5Ac Reverts the Malignant Phenotype of Pancreatic Cancer Cells, and Reduces Tumor Volume and Favors T-Cell Infiltrates in Mice Miró, Laura López, Júlia Guerrero, Pedro E. Martínez-Bosch, Neus Manero-Rupérez, Noemí Moreno, Mireia Ortiz, M. Rosa Llop, Esther Navarro, Pilar Peracaula, Rosa Cancers (Basel) Article SIMPLE SUMMARY: An increase of sialic acid in the cancer cells’ surface is a hallmark of tumours, including pancreatic cancer, and it has been related to tumour malignancy and immune suppression. In this work, we have assessed for the first time the potential of the sialyltransferase inhibitor, Ac(5)3F(ax)Neu5Ac, to reduce tumor sialylation in pancreatic cancer and to revert its malignant phenotype. We have shown that Ac(5)3F(ax)Neu5Ac treatment on human pancreatic cancer cells decreased their sialic acid, reduced their E-selectin adhesion—the prior step to tumour extravasation—and their migration and invasion capabilities. In addition, subcutaneous pancreatic tumours generated on immunocompetent mice that were treated with Ac(5)3F(ax)Neu5Ac showed a reduced growth and increased tumour infiltrating lymphocytes. These results show that the targeting of tumour sialoglycans in pancreatic cancer reverts its malignant phenotype and favours anti-tumour immune surveillance, which opens the way to use sialyltransferase inhibitors as a novel therapeutic strategy against this dismal disease. ABSTRACT: Hypersialylation is a feature of pancreatic ductal adenocarcinoma (PDA) and it has been related to tumor malignancy and immune suppression. In this work, we have evaluated the potential of the sialyltransferase inhibitor, Ac(5)3F(ax)Neu5Ac, to decrease tumor sialoglycans in PDA and to revert its malignant phenotype. Sialoglycans on PDA cells were evaluated by flow cytometry, and the functional impact of Ac(5)3F(ax)Neu5Ac was assessed using E-selectin adhesion, migration, and invasion assays. PDA tumors were generated in syngeneic mice from KC cells and treated with Ac(5)3F(ax)Neu5Ac to evaluate tumor growth, mice survival, and its impact on blocking sialic acid (SA) and on the tumor immune component. Ac(5)3F(ax)Neu5Ac treatment on human PDA cells decreased α2,3-SA and sialyl-Lewis(x), which resulted in a reduction in their E-selectin adhesion, and in their migratory and invasive capabilities. Subcutaneous murine tumors treated with Ac(5)3F(ax)Neu5Ac reduced their volume, their SA expression, and modified their immune component, with an increase in CD8(+) T-lymphocytes and NK cells. In conclusion, Ac(5)3F(ax)Neu5Ac treatment weakened PDA cells’ malignant phenotype, thereby reducing tumor growth while favoring anti-tumor immune surveillance. Altogether, these results show the positive impact of reducing SA expression by inhibiting cell sialyltransferases and open the way to use sialyltransferase inhibitors to target this dismal disease. MDPI 2022-12-12 /pmc/articles/PMC9776040/ /pubmed/36551619 http://dx.doi.org/10.3390/cancers14246133 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Miró, Laura
López, Júlia
Guerrero, Pedro E.
Martínez-Bosch, Neus
Manero-Rupérez, Noemí
Moreno, Mireia
Ortiz, M. Rosa
Llop, Esther
Navarro, Pilar
Peracaula, Rosa
Sialyltransferase Inhibitor Ac(5)3F(ax)Neu5Ac Reverts the Malignant Phenotype of Pancreatic Cancer Cells, and Reduces Tumor Volume and Favors T-Cell Infiltrates in Mice
title Sialyltransferase Inhibitor Ac(5)3F(ax)Neu5Ac Reverts the Malignant Phenotype of Pancreatic Cancer Cells, and Reduces Tumor Volume and Favors T-Cell Infiltrates in Mice
title_full Sialyltransferase Inhibitor Ac(5)3F(ax)Neu5Ac Reverts the Malignant Phenotype of Pancreatic Cancer Cells, and Reduces Tumor Volume and Favors T-Cell Infiltrates in Mice
title_fullStr Sialyltransferase Inhibitor Ac(5)3F(ax)Neu5Ac Reverts the Malignant Phenotype of Pancreatic Cancer Cells, and Reduces Tumor Volume and Favors T-Cell Infiltrates in Mice
title_full_unstemmed Sialyltransferase Inhibitor Ac(5)3F(ax)Neu5Ac Reverts the Malignant Phenotype of Pancreatic Cancer Cells, and Reduces Tumor Volume and Favors T-Cell Infiltrates in Mice
title_short Sialyltransferase Inhibitor Ac(5)3F(ax)Neu5Ac Reverts the Malignant Phenotype of Pancreatic Cancer Cells, and Reduces Tumor Volume and Favors T-Cell Infiltrates in Mice
title_sort sialyltransferase inhibitor ac(5)3f(ax)neu5ac reverts the malignant phenotype of pancreatic cancer cells, and reduces tumor volume and favors t-cell infiltrates in mice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776040/
https://www.ncbi.nlm.nih.gov/pubmed/36551619
http://dx.doi.org/10.3390/cancers14246133
work_keys_str_mv AT mirolaura sialyltransferaseinhibitorac53faxneu5acrevertsthemalignantphenotypeofpancreaticcancercellsandreducestumorvolumeandfavorstcellinfiltratesinmice
AT lopezjulia sialyltransferaseinhibitorac53faxneu5acrevertsthemalignantphenotypeofpancreaticcancercellsandreducestumorvolumeandfavorstcellinfiltratesinmice
AT guerreropedroe sialyltransferaseinhibitorac53faxneu5acrevertsthemalignantphenotypeofpancreaticcancercellsandreducestumorvolumeandfavorstcellinfiltratesinmice
AT martinezboschneus sialyltransferaseinhibitorac53faxneu5acrevertsthemalignantphenotypeofpancreaticcancercellsandreducestumorvolumeandfavorstcellinfiltratesinmice
AT manerorupereznoemi sialyltransferaseinhibitorac53faxneu5acrevertsthemalignantphenotypeofpancreaticcancercellsandreducestumorvolumeandfavorstcellinfiltratesinmice
AT morenomireia sialyltransferaseinhibitorac53faxneu5acrevertsthemalignantphenotypeofpancreaticcancercellsandreducestumorvolumeandfavorstcellinfiltratesinmice
AT ortizmrosa sialyltransferaseinhibitorac53faxneu5acrevertsthemalignantphenotypeofpancreaticcancercellsandreducestumorvolumeandfavorstcellinfiltratesinmice
AT llopesther sialyltransferaseinhibitorac53faxneu5acrevertsthemalignantphenotypeofpancreaticcancercellsandreducestumorvolumeandfavorstcellinfiltratesinmice
AT navarropilar sialyltransferaseinhibitorac53faxneu5acrevertsthemalignantphenotypeofpancreaticcancercellsandreducestumorvolumeandfavorstcellinfiltratesinmice
AT peracaularosa sialyltransferaseinhibitorac53faxneu5acrevertsthemalignantphenotypeofpancreaticcancercellsandreducestumorvolumeandfavorstcellinfiltratesinmice